



# Vivli

CENTER FOR GLOBAL CLINICAL RESEARCH DATA

VIVLI.ORG

Vivli's **mission** is to promote, coordinate, and facilitate clinical research data sharing through the creation and implementation of a sustainable global data sharing enterprise.

Vivli partners with the AD Data Initiative to make it easier for researchers to access the Alzheimer's data that Vivli holds is accessible through the AD Workbench. This interoperability creates the greatest utility for researchers while still maintaining the safety and security of participants' information

## Interoperability Partnership



**Alzheimer's Disease  
Data Initiative**

*Specific focus on AD and  
supporting AD research*

+



**Vivli**

CENTER FOR GLOBAL CLINICAL RESEARCH DATA

=

Greatest utility  
for researchers  
while protecting  
participants' privacy

*Leveraging existing governance  
processes and agreements*

The screenshot displays the Vivli website's search interface. At the top, the Vivli logo and navigation links (Home, About, Members, News & Events, Resources, Portals, Find Studies) are visible. A banner at the top reads "We are committed to advancing the knowledge around the COVID-19 pandemic" with buttons for "Share trials" and "Search for trials". Below this, the "KEYWORD SEARCH" section is active, showing the search term "Alzheimer's" in a red-bordered box. The search results are displayed in a grid with filters for STUDY DESIGN, SPONSOR INFORMATION, LOCATION, and START/END DATE. At the bottom, a red-bordered box highlights the result count: "91 Studies".

*More than 90 studies related to Alzheimer's are available for searching and requesting on Vivli. This includes studies from AbbVie, Astellas, AstraZeneca, Biogen, Boehringer Ingelheim, GSK, Johnson & Johnson, Lilly, and Takeda.*


## About Vivli

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform. Our focus is on sharing individual participant-level data from completed clinical trials to serve the international research community. We act as a neutral broker between data contributor, data user and the wider data sharing community.

## Our Platform

The Vivli platform includes an independent data repository, in-depth search engine and a secure research environment. Users can search listed studies, request data sets from data contributors, aggregate data, or share data of their own. The enhanced search engine is designed to index clinical trial metadata. The secure research environment includes access to robust analytical tools or data can be downloaded with permission.

## Vivli by the Numbers



## Alzheimer's Disease Publications that utilized data accessible via Vivli

Lead Investigator	Institution	Public Disclosure	Data Contributor(s)
Iris Sommer	University Medical Center Groningen	d'Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. Published online June 26, 2023. doi:10.1001/jamaneurol.2023.1835	AbbVie, GSK, Johnson & Johnson
Wiesje van der Flier	Amsterdam UMC, VUmc	Dubbelman, M.A., Vromen, E.M., Tijms, B.M., Ottenhoff, L., Vijverberg, E.G., Prins, N.D., van der Flier, W.M. and Sikkes, S.A., 2023, July. P1-743 - Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach. In Alzheimer's Association International Conference. ALZ. No doi	Boehringer Ingelheim, GSK, Johnson & Johnson, Lilly
Neil Oxtoby	University College London	C. Shand, N.P. Oxtoby. INVESTIGATING TREATMENT EFFECT HETEROGENEITY IN DATA-DRIVEN SUBGROUPS OF TOMMORROW. Journal of Prevention of Alzheimer's Disease. 2023; Abstract P004, pg. S57	Takeda
Sudhir Sivakumaran	Critical Path Institute	Sudhir Sivakumaran, Yashmin Karten, Nicholas Cullen, Corissa Lau, Eileen Priest, Hazel White, Klaus Romero, Michael Irizarry. Accelerating drug development through precompetitive data sharing and collaboration in the Critical Path for Alzheimer's Disease (CPAD) Consortium. Abstract P0325/#231, p325.	Lilly
Sharon Straus	St. Michael's Hospital	Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012 doi: 10.1136/bmjopen-2021-053012	AbbVie

To find out more about Vivli, please visit [vivli.org](https://vivli.org) or contact [support@vivli.org](mailto:support@vivli.org)